Cyramza approved for stomach cancer

(HealthDay)—Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach or of the area where the esophagus joins the stomach (the gastroesophageal junction).

Stomach cancer, primarily affecting older people, is expected to be diagnosed in more than 22,000 Americans this year and cause the deaths of about 10,990 people, the FDA said Monday in a news release.

Cyramza works by blocking the blood supply to tumors. It's been approved in advanced cases where the tumor can't be surgically removed, or where the cancer has spread despite the use of other anti-cancer drugs, the agency said.

Cyramza's safety and effectiveness were evaluated in clinical studies involving 355 people. Participants who received the drug lived for an average of 5.2 months compared to 3.8 months among those who took a placebo, the FDA said.

Common side effects included diarrhea and .

Cyramza is marketed by Eli Lilly, based in Indianapolis.

More information: The FDA has more about this approval.

Related Stories

Nexavar approval expanded for common thyroid cancer

date Nov 24, 2013

(HealthDay)—U.S. Food and Drug Administration approval for the anti-cancer drug Nexavar (sorafenib) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid ...

Cometriq approved for rare thyroid cancer

date Nov 29, 2012

(HealthDay)—Cometriq (cabozantinib) has been approved by the U.S. Food and Drug Administration to treat modullary thyroid cancer that has spread to other parts of the body, the agency said Thursday.

Zaltrap approved for advanced colorectal cancer

date Aug 04, 2012

(HealthDay) -- Zaltrap (ziv-afilbercept) has been approved by the U.S. Food and Drug Administration in combination with a FOLFIRI chemotherapy regimen for adults with advanced metastatic (spreading) colorectal cancer, the ...

Recommended for you

Study supports HPV vaccination guidelines

date 5 hours ago

(HealthDay)—New research finds that young women who get the HPV vaccine gain significant protection against infection in three parts of the body if they haven't already been exposed to the human papillomavirus.

Teva offers to buy Mylan in $40.1B cash-and-stock deal

date 10 hours ago

Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring ...

FDA warns of bogus botox

date Apr 20, 2015

(HealthDay)—Counterfeit Botox may have been distributed to doctors' offices and medical clinics across the United States, the U.S. Food and Drug Administration warns.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.